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Diagnostic Effectiveness of Lead aVR as a STEMI Equivalent
Karen Hayes & Phung Vu

Abstract
Background: Acute coronary syndrome (ACS) encompasses a collection of three
acute processes related to myocardial ischemia. These include: unstable angina, nonST elevation myocardial infarction (NSTEMI), and ST elevation myocardial
infarction (STEMI). The 12-lead electrocardiogram (ECG) is a crucial tool in the
diagnosis and risk stratification of ACS. Unlike the other 11 leads, lead augmented
Vector Right (aVR) has been long neglected until recent years. Recent investigations
have shown that an analysis of ST-segment shift in lead aVR provides useful
information on the coronary angiographic anatomy and risk stratification in ACS.
This implies that the use of lead aVR can be effective in the early detection and extent
of tissue ischemia, increasing the chances of acute myocardial infarction (AMI)
survival. Objective: The purpose of this review is to determine whether the use of
lead aVR can be used as a STEMI equivalent compared to the standard STEMI
criteria as defined by the American Heart Association to predict proximal left anterior
descending (LAD) or left main coronary artery (LMCA) occlusion in order to
decrease door to balloon time and overall mortality. Methods: A PubMed search was
conducted using the following search terms and filters: aVR, STEMI, and myocardial
infarction articles in the last 10 years, English language, randomized control trials,
meta-analysis reviews. Articles were excluded if not specific to lead aVR, emphasis
on treatment rather than diagnosis, no full text of the article was available, and low
participant numbers. Conclusion: While the use of lead aVR in insolation as a
STEMI equivalent remains unclear, there is evidence supporting that ST elevation in
lead aVR is associated with higher mortality in the presence of a recognized STEMI.
It is also suggested that ST elevation (STE) in lead aVR may involve the LAD or all
three main coronary arteries (triple vessel disease). This is promising in early
recognition of tissue ischemia and can be used as a potential marker of disease
severity.
Keywords: Left Anterior Descending Coronary Artery (LAD); Left Main Coronary Artery (LMCA);
Left Bundle Branch Block (LBBB); Right Bundle Branch Block (RBBB); Percutaneous Coronary
Intervention (PCI); Coronary artery disease (CAD); ST segment elevation myocardial infarction
(STEMI); Non-ST segment elevation myocardial infarction (NSTEMI), ST segment elevation (STE).

Introduction
The 12 lead ECG is a diagnostic tool that aids in the evaluation of coronary artery disease
(CAD). A ST segment elevation myocardial infarction (STEMI) is a distinct pattern detected on
12-lead ECG and is a type of myocardial infarction that indicates occlusion of one of the main
coronary arteries supplying the heart muscle.1 Clinicians are provided a strict set of criteria as to
what qualifies as a STEMI and subsequent emergent activation of the cardiac catheterization lab
for reperfusion therapy. The American Heart Association defines a STEMI as ST elevation at the
J point in at least two contiguous leads. Contiguous leads view the same anatomical portion of
the left ventricle. The 11 leads are divided based on the portion of the left ventricle they are
viewing; inferior leads (II, III, and aVF), septal leads (V1 and V2), anterior leads (V3 and V4),
and lateral leads (I, aVL, V5, and V6). In this functional categorization, the remaining lead, aVR,
is frequently disregarded. However, lead aVR may provide the clinician with valuable clinical

information due to its different directional orientation than all other leads.2 It has been proposed
that ST elevation in aVR should be treated as a STEMI equivalent given the appropriate clinical
context. With clinical symptoms of myocardial ischemia, ST segment elevation in aVR greater
than or equal to 1 mm is suggested to signify significant proximal LAD or LMCA occlusion. Just
as reciprocal changes add to the validity of a classic STEMI, reciprocal changes represented as
widespread ST depression and ST elevation in aVR greater than V1, adds to the validity of
significant left main disease. The left main coronary artery (LMCA) arises from the aorta just
above the aortic valve and is responsible for supplying a significant portion of myocardium.
LMCA occlusion can lead to devastating consequences, including cardiogenic shock and death,
especially if unrecognized. Lead aVR may have the ability to identify these high-risk patients
and activate the cardiac catheterization lab earlier for intervention, decreasing ischemic
complications.3
While the mechanism behind ST segment elevation in lead aVR is unclear, it is suggested
that it may be the result of being electrically opposite of the left sided leads (I, aVL, V4-V6).
Occlusion of the LMCA would result in ST depression in the left sided leads with reciprocal
changes in aVR manifested by ST elevation. Another proposed mechanism involves the fact that
aVR looks directly at the right side of the heart (along with V1), unlike the other 10 leads. The
basal portion of the interventricular septum is located in the right upper portion of the heart and
is supplied by the first branch of the left anterior descending coronary artery (LAD). It would
therefore suggest that the culprit lesion would be located in the proximal LAD or LMCA causing
insufficient coronary artery blood flow.4
Many studies have been performed looking at the diagnostic ability of aVR as well as
potential limitations. The presence of ST elevation in lead aVR may not be entirely specific to
LMCA or proximal LAD occlusion. It may also suggest the presence of triple vessel disease or
diffuse subendocardial ischemia. Furthermore, some studies argue that it is unable to distinguish
between LMCA occlusion versus insufficiency, indicating some blood flow is still present. This
study aims to investigate if the predictive value of ST elevation in lead aVR is high enough to be
used as a diagnostic STEMI equivalent.
PICO
P: Patients aged 40 and above presenting with acute coronary syndrome (ACS) as defined by the
presentation of STEMI, NSTEMI, or unstable angina.
I: Evaluation of lead aVR as a STEMI equivalent
C: Standard STEMI criteria as defined by the American Heart Association
O: To predict proximal LAD or LMCA occlusion in order to decrease door to balloon time and
overall mortality
Clinical Question
Patients aged 40 and above presenting with acute coronary syndrome as defined by the
presentation of STEMI, NSTEMI, or unstable angina, does the use of Lead aVR as a STEMI
equivalent provide an earlier diagnosis of proximal LAD or LMCA occlusion in order to
decrease door to balloon time and overall mortality compared to standard STEMI criteria.

Methods
An initial literature search of PubMed using the search terms “aVR” and “STEMI” and
“myocardial infarction” yielded 16 results. Inclusion criteria included randomized control trials
and meta-analyses with publication dates within the last 10 years. No duplicate articles were
removed. 11 studies were screened for relevance to the research subject matter. For example,
some studies were removed because they were not specific to lead aVR, and some focused more
on treatment rather than diagnosis. A total of three articles were selected to be included in this
analysis based on relevance and population size.
Records identified through database
searching
(n = 16)

List Databases Search:
PubMed
List Search Term:
aVR, STEMI myocardial infarction

# Records after duplicates removed
(n = 16)

Records screened
(n = 11)

Full-text articles assessed for
eligibility
(n = 6)

Records excluded
(n = 5)
Reasons for exclusion: Not
specific to aVR

Full-text articles excluded
(n = 3)
Reasons for exclusion:
Treatment specific, not diagnosis of
LAD/LMCA occlusion

Studies included in qualitative synthesis
(n = 3)
Name of study:
Relationship of ST elevation in lead aVR with angiographic findings
and outcome in non-ST elevation acute coronary syndromes.
aVR ST elevation: an important but neglected sign in ST elevation
acute myocardial infarction
Utility of lead aVR for identifying the culprit lesion in acute
myocardial infarction
Reasons for including:
Right population, adequate population size in review article

This PRISMA flow chart helped identify the studies involved in the analysis. The articles that made it to the screening
phase were evaluated by two reviewers based on criteria highlighted in the chart and the outcome measurements used by the
studies that addressed the clinical question.
http://prisma-statement.org/prismastatement/flowdiagram.aspx

Results
Study #1:
Relationship of ST elevation in lead aVR with angiographic findings and outcome in non-ST
elevation acute coronary syndromes.5
Objective:
In the setting of a NSTEMI, the goal of this study was to evaluate the connection between ST
elevation in lead aVR with coronary artery angiographic findings on cardiac catheterization, as
well as with mortality rates.
Study Design:
This study is an ongoing prospective electrocardiographic sub-study of the Global
Registry of Acute Coronary Events (GRACE). The GRACE registry analyzes patient populations
with ACS in 13 countries. The electrocardiographic sub-study used 39 sites in 11 countries, with
8,202 patients initially enrolled. Patient inclusion and exclusion criteria for the prospective study
were based on clinical symptoms and ECG findings (Table 1).
Table 1. Inclusion and exclusion criteria for study participation in the electrographic sub-study
of the GRACE registry.5
Inclusion Criteria

Exclusion Criteria

At least 18 years old

Serious comorbidity

Admitted with non-ST segment elevation
myocardial infarction

Poor quality ECG
Ventricular or paced rhythm
STEMI on ECG
Left bundle branch block on ECG

A total of 5,064 patients met inclusion and exclusion criteria and formed the sub-study
cohort. The patients were divided into three groups based on ST segment elevation in lead aVR:
no ST elevation, minor ST elevation (0.5-1mm), and major ST segment elevation (>1mm). The
GRACE risk score evaluates for age, gender, amount of ST segment deviation, vital signs,
biomarkers, and Killip class. A logistic regression was therefore utilized to adjust for these
confounding variables to be able to evaluate ST aVR ST elevation independently. Reading of the
ECGs were all performed at the Canadian Heart Research Centre. The clinical data and outcomes
were blinded to the interpreter. ST segment deviation was measured at the J point and rounded to
the nearest 0.5mm.
Patients were followed up with six months after hospital discharge via telephone call.
88.2% of those entering the study were able to be followed up with. The Kaplan-Meier method
was utilized to produce survival curves, and hazard ratios were calculated.

Study Results:
Of all the patients in the substudy diagnosed with a NSTEMI, 5.8% were found to have
0.5-1mm of ST elevation in lead aVR. 1.5% had greater than 1mm of ST segment elevation in
aVR. Overall, patients with ST segment elevation in aVR were found to have concurrent diffuse
ST depression in other leads. These patients in general were also older, presented with more
tachycardia, and had a worse Killip class. It was found that patients with greater than 1mm of ST
elevation in lead aVR had higher in hospital mortality rates compared to those with no or minor
aVR ST elevation (P=0.03). Mortality rate was also evaluated six months after hospital
discharge. There was a 7.6% mortality rate for patients that presented with no STE in aVR,
12.7% for those with minor elevation, and 18.3% for those with major STE (Figure 1).

Figure 1. Kaplan-Meier curves analyzing relationship between ST elevation in aVR with
mortality rates.5
It appears as if minor or major STE in aVR correlates with an increased mortality rate
when compared to those with no ST deviation in aVR. However, when analysis was performed
with the multivariable Cox regression tool analyzing components of the GRACE risk score, it
was shown that aVR STE was not an independent predictor of mortality. Cox regression tool
determined that the effects of the predictor variables listed in the GRACE risk score were
maintained over time with the addition that it had no effect on the survival time of patients.
The study also looked at the potential of STE in aVR to predict the culprit lesion in an
acute myocardial infarction. It was found that the presence of STE in aVR was significantly
more common in left main coronary artery occlusion or triple vessel disease than any other
location (Table 2). The authors concluded that the presence of STE greater than 1mm in lead
aVR was predictive of left main coronary artery disease and/or triple vessel disease.

Table 2. Angiographic findings comparing patients with no, minor, or major STE in lead aVR.5
% of
patients

Overall
(N=2416)

No STE in
aVR
(n=2252)

0.5-1mm
STE in aVR
(n=30)

>1mm STE
in aVR
(n=34)

P value for
trend

LAD stenosis

59.6

59.2

66.2

61.8

0.20

LCx Stenosis

50.0

48.6

70.8

64.7

<.001

RCA stenosis

55.0

54.4

61.5

70.6

0.02

LM coronary
stenosis

5.4

5.1

9.2

14.7

0.002

3-vd

24.0

23.3

32.3

44.1

<0.001

LM/3 VD

27.0

26.1

36.2

55.9

<0.001

Overall, this study concluded that while STE in aVR alone may not have diagnostic
potential, it was a predictor of severity and extent of disease. The unadjusted in-hospital and 6month mortality were significantly higher in those with major STE in aVR (>1mm) as opposed
to those with no or minor STE (0.5-1mm) in lead aVR. While these findings were not supported
in isolation, it was suggested that in combination with widespread ST depression, major STE in
lead aVR (>1mm) may be used to identify patients with severe coronary artery disease.
Study Critique:
There were many strengths to this study. The patient population consisted of ACS
patients diagnosed with an NSTEMI. This produced a patient population that eliminated
variables such as ST elevation in other leads besides aVR, but still necessitated a cardiac
catheterization in order to verify results. The study population was also from 11 different
countries in varying settings, which may add to the generalizability of the results. The study also
adjusted for multiple confounding variables by utilizing the GRACE risk model. The GRACE
risk model allowed the study to look at lead aVR in isolation to determine its prognostic value.
Bias were minimized by utilizing a blinded method in interpreting the ECGs.
Some limitations of this study include the population size. While there were 5,064
patients overall, only 368 presented with STE in lead aVR. Of those 368 patients, there were 76
with STE in lead aVR greater than 1mm. Of note, not all patients received cardiac
catheterizations depending on their clinical presentation and the physician discretion. This could
have skewed the overall data on ability to predict severity and location of coronary disease.
There was also an 11.3% loss to follow up at six months for undisclosed reasons. It was also
suggested that the prognostic value of STE in lead aVR might have been miscalculated given
that the ECGs analyzed were those performed on admission to the hospital. This does not allow
for trending of ST segment deviation throughout the course of hospitalization and disease
progression.

Study #2:
aVR ST elevation: an important but neglected sign in ST elevation acute myocardial infarction.6
Objective:
The goal of this study was to determine the prognostic value of ST elevation in lead aVR as an
indicator of mortality risk with an acute myocardial infarction.
Study Design:
This study utilized data from the Hirulog and Early Reperfusion/Occlusion-2 (HERO-2)
trial to determine if there was a relationship between ST segment elevation in lead aVR and 30day mortality. The goal of the initial HERO-2 trial was to analyze the effect of different
anticoagulation agents on 30-day mortality in patients receiving fibrinolytic therapy during an
acute myocardial infarction. In the HERO-2 study, 17,073 patients were considered for
evaluation. Patient inclusion and exclusion criteria for the trial was based on clinical symptoms
and ECG findings (Table 3).
Table 3. Inclusion and exclusion criteria for study participation in HERO-2 trial.6
Inclusion Criteria

Exclusion Criteria

>30 minutes of ischemic chest pain with ST
segment MI or new onset LBBB

Chest pain not consistent with ischemia
Chest pain for greater than 6 hours

Within 6 hours of symptom onset

No ECG evidence of myocardial infarct

Patients were randomized to receive either bivalirudin or heparin, as well as streptokinase
and aspirin. During the protocol, the patients received ECG tracings at random and at 60 minutes
post administration of streptokinase, which was utilized as a fibrinolytic agent. The ECGs were
interpreted by eight trained technicians at the Green Lane Hospital. Technicians were blinded to
study participants and treatment groups. The HERO-2 trial concluded that there was no statistical
difference between the two groups.
This sub-study obtained the information from the HERO-2 trial and analyzed the ECGs.
The ECGs were all consistent with an acute MI and were included/excluded based on technical
findings (Table 4). Of the 17,073 patients that were studied in the HERO-2 trial, 325 were
excluded due to the presence of a left ventricle conduction delay (LBBB) obscuring the value of
the ST segment, 691 due to RBBB, and 717 due to ventricular rhythm, paced rhythm, evidence
of preexcitation syndrome, or poor-quality ECG. After exclusion criteria were applied, 15,315
patients remained in the study.
Table 4. Inclusion and exclusion criteria for lead aVR study participation.6
Inclusion Criteria

Exclusion Criteria

Sinus or atrial rhythm

Interventricular conduction delay (LBBB)

Good quality ECG tracing

Ventricular or paced rhythm

Pre-excitation syndrome
Poor quality ECG with artifact
The ST segment was analyzed in all 12 leads ST segment deviation was measured 60ms
past the J point, and rounded to the nearest 0.5mm. This information was utilized to perform
statistical analysis via logistic regression to determine if ST elevation in lead aVR greater than or
equal to 1 mm was prognostic of 30-day mortality. The logistic regression model is a predictive
analysis tool that looks at the relationship between two variables. In this case, the model was
adjusted for total amount of baseline ST segment elevation/depression in other 11 leads, with the
addition of age, sex, vital signs, time of symptom onset, and prior AMI.
Study Results:
Of the 15,315 patients studied with an acute MI, it was found that 7,299 were anterior in
location, and 8,016 with inferior in location. There were 779 patients presenting with an anterior
MI with ST segment elevation in lead aVR (greater than 1mm), and 365 of the patients with an
inferior MI had ST elevation in aVR (greater than 1mm). In comparison to the patients without
ST segment elevation in aVR, it was generally noted that patients with elevation tended to be
older and had a history of prior MI.
The study concluded that patients with ST segment elevation in aVR greater than or equal
to 1mm, regardless of infarct location, had a higher 30-day mortality rate. Those with an anterior
MI and ST elevation in aVR had a 15.5% mortality rate compared to those without aVR findings
at 12.2% (P=0.0069). Those with an inferior MI had a 15.9% mortality rate compared to 6.5%
without aVR involvement (P value less than 0.0001). It was concluded that ST elevation in lead
aVR provided important information on prognosis after an acute myocardial infarction.
Study Critique:
The limitations of this study include the population utilized and location. The study
participants were initially chosen based on criteria for the HERO-2 trial, which included those
patients who qualified for both anticoagulation and fibrinolytic therapy. This may differ from
clinical populations, in that not all patients are candidates for both anticoagulation and
fibrinolytic therapies. The HERO-2 trial was also performed in non-Western countries, which
could have contributed to overall mortality if there was no access to primary PCI. Other risk
factors may have also played a contributory role in mortality to include age and previous history
of AMI. It was stated that there was a general trend (although not analyzed statistically) that the
older individuals with previous history tended to have ST elevation in aVR. Therefore, aVR may
be used as a simple way to quickly analyze risk factors in a clinical situation where you may not
be able to obtain clinical information.
A strength of this study was the population size. It looked at a large cohort of individuals
diagnosed with an acute MI based on ECG findings. While the study looked at aVR STE in the
context of a previously recognized STEMI based on standard criteria, rather than in isolation, it
still provided valuable information of the utility of aVR. Establishing the prognostic value of
aVR will hopefully lead to further studies about the implementation of aVR as a STEMI
equivalent.

Study #3:
Utility of lead aVR for identifying the culprit lesion in acute myocardial infarction.7
Objective:
This literature review aimed to evaluate lead aVR as a tool to identify the vessel involved
in an acute myocardial infarction.
Study Design
A systematic search strategy was utilized, and data pooled in order to analyze lead aVR
as a diagnostic tool. MEDLINE and Google Scholar were searched for relevant data, with key
term “aVR,” “ischemia,” “myocardial infarction,” and “ST segment elevation and depression.”
Studies were evaluated for relevance and confounding factors for inclusion and exclusion criteria
(Table 5).
Table 5. Inclusion and exclusion criteria for study participation.7
Inclusion Criteria

Exclusion Criteria

Typical Chest Pain

Left bundle branch block

Clinically significant ST deviations

Left ventricular hypertrophy

Elevation of coronary enzymes

Previous history of MI

Coronary angiography with known culprit lesion

Cardiac surgery

The information obtained from the literature review was placed in 2 x 2 contingency
tables and the Fisher Exact test was utilized. The Fisher Exact test is used to determine statistical
significance when analyzing the association between two variables. The data collection and
statistical analysis was performed by two independent researchers. Lead aVR was evaluated in
the context of predicting left main stenosis (LMS) and proximal LAD occlusion. In the
assessment of LMS, five studies were investigated with patients meeting NSTEMI criteria. ST
segment elevation was measured 60ms beyond the J point in lead aVR. A cutoff of 0.05-0.1mV
was established for J point elevation significance. Seven articles were analyzed looking at the
predictive value of ST elevation of aVR in diagnosing a proximal LAD lesion above the first
septal branch. ECGs were evaluated with evidence of ST elevation in anterior leads V2-V4.
Study Results
The summary of results from the five studies analyzing the ability of STE in lead aVR to
predict LMS is shown in Table 6. There is inconsistent positive predictive values but relatively
reliable negative predictive values. The high negative predictive value suggests that in the
absence of STE in lead aVR, LMS is unlikely the culprit coronary artery.

Table 6: Lead aVR STE for Diagnosis of LMS in NSTEMI.7
Studies

Population aVR
STE
(mV)

LMS Sensitivity
Cases (%)

Specificity
(%)

PPV (%)

NPV (%)

Barrabes 775
et al

0.1

9

77

64

5

99

Henguss
amee et
al

26

0.05

5

80

76

44

94

Kosuge
et al

310

0.05

60

78

86

57

95

Rostoff
et al

134

0.05

44

68

73

56

83

Yu et al

91

0.1

9

89

84

38

99

Table 7 summarizes the data collected from the seven studies evaluating the ability of
STE in aVR to predict proximal LAD lesions. With concurrent STE in V2-V4 (anterior STEMI),
STE in lead aVR is shown to be beneficial in predicting proximal LAD involvement, with a high
positive predictive value and specificity.
Table 7: Lead aVR STE for Diagnosis of proximal LAD lesion.7
Studies

Population # Relevant
Lesions

Sensitivity
(%)

Specificity
(%)

PPV (%)

NPV (%)

Pooled
Data

489

47

96

91

69

218

Study Critique
This review acknowledged aVR as an indicator of disease severity but aimed to
determine if STE in aVR could determine location of the culprit lesion in an acute myocardial
infarction. There were many limitations in this review. The studies used all had different cut offs
as far as what was considered significant lesions (anywhere from 50 to 75%), as well as different
cut-off values for what mV criteria was considered significant ST elevation. Lead aVR was also
not analyzed in isolation from the presence of an anterior myocardial infarction (STE in leads
V2-V4). Other potential limitations leading to bias were the inconsistency of population
demographics, as well as non-consistent use of blinding in the studies. A positive of this
literature review was its organization and consolidation of information in easy to follow tables.
It presents the information in a way that the conclusion can clearly be drawn that lead aVR is not
sensitive enough to be used in isolation, but rather should be looked in context with a coexisting
STEMI.

Discussion
It is well established that earlier intervention with an acute MI with fibrinolytics or
primary coronary intervention with ballooning/stenting produces better outcomes for patients.1 A
strict set of guidelines have been established as to what qualifies as a STEMI in order to
recognize these patients with acute coronary artery occlusion and therefore emergently activate
the cardiac catheterization lab without the need for biomarkers.2 The purpose of this
investigation was to determine if there was strong enough evidence to support the use of STE in
lead aVR as a STEMI equivalent, suggesting LMCA or proximal LAD occlusion. Recognition of
these patients with significant LMCA/LAD disease should be of high priority due to the large
amount of myocardium they supply and subsequent ischemic consequences.
According to table 7, the sensitivity is 47% and specificity is 96% for lead aVR STE for
diagnosis of proximal LAD lesion. The calculated positive likelihood ratio is 11.75 vs the
negative likelihood ratio is 0.55. According to the nomogram, when a patient has a positive test
for lead aVR STE, there is a 91% that proximal LAD lesion is involved. On the other hand, when
there is a negative test result for lead aVR STE, there is a 69% that the proximal LAD is not
involved. Since both PPV and NPV values are high, it indicates that ECG is a powerful
assessment tool to determine whether proximal LAD is involved in lead aVR STE.

While lead aVR is often referred to as the “forgotten lead,” it has gained popularity over
the last 10 years. The 2013 ACC/AHA STEMI guidelines even incorporate lead aVR in the
decision to administer fibrinolytics. They state that if there is ST elevation in lead aVR with
associated ST depression, fibrinolytics are indicated.2 However, there is debate on the evidence
used to formulate this statement. The debate stems on how to define coronary artery “occlusion.”
While some assume that the word occlusion means there is complete blockage of the left main,
some studies reference any stenosis greater than 50%. At 50% stenosis, fibrinolytics and PCI
may not be indicated. It is therefore suggested that ST elevation in lead aVR should signify left
main insufficiency rather than occlusion, and not be classified as a STEMI equivalent.8 The three
studies analyzed in this investigation support these suggestions. Yan et al reported that there was
an increased mortality rate in hospital and at 6 months follow up in individuals with STE in lead
aVR greater than 1mm. It also showed the predictive value of STE to show significant left main

stenosis or triple vessel disease. However, these results proved to be insignificant when aVR was
viewed in isolation using a regression analysis model.5 Gao et al was a meta-analysis that
concluded that there was a significant increase in 30-day mortality in patients with STE in lead
aVR greater than 1mm, but no conclusion was drawn about its predictive ability in isolation.6
Kuhl et al concluded that in the absence of STE in lead aVR, left main stenosis was statistically
unlikely. However, with highly variable positive predictive values, the authors are unable to
make a recommendation on the diagnostic ability of lead aVR.7
Conclusion
There is evidence to suggest that ST elevation in lead aVR is associated with higher
mortality in the presence of a recognized STEMI, as well as an association with subendocardial
ischemia in a patient with an NSTEMI and/or diffuse ST depression. It is also suggested that in
the setting of a patient with ACS and STE in lead aVR, the culprit lesion is not limited to the left
main coronary artery, but rather may also indicate the LAD or involvement of all three main
coronary arteries (triple vessel disease). The clinical use of lead aVR in isolation as a STEMI
equivalent remains unclear. It is therefore concluded that without further studies to evaluate its
prognostic ability, there is not strong enough evidence to support STE in lead aVR as a STEMI
equivalent, but rather a potential marker of disease severity.
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